Navigation Links
Echo Therapeutics Expands Into New Headquarters in Philadelphia
Date:5/5/2011

PHILADELPHIA, May 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the relocation of its corporate headquarters from Franklin, MA to Philadelphia, PA.

The new office is located in the heart of Philadelphia's Center City Business District at 8 Penn Center.  Echo will continue to maintain and grow its Franklin office as its key operations hub where its engineering and product personnel are located.

"Since Echo Therapeutics' inception, the company has maintained its headquarters in Franklin where we have enjoyed a rewarding history of growth and success," stated Patrick Mooney, M.D., Echo's Chairman and CEO.  "The new headquarters responds directly to Echo's growing and evolving business and will accommodate both recent team expansion and additional hires planned for 2011 and beyond."

Echo operates at the following locations:

8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 (Headquarters)

10 Forge Parkway, Franklin, MA 02038

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. For More Information:Patrick T. Mooney, M.D.

Media: Richard SternChairman and Chief Executive Officer

Stern &Co.(215) 717-4100

(212) 888-0044Connect With Us:- Visit our website at www.echotx.com

- Follow us on Twitter at www.twitter.com/echotx<
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
2. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
3. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
4. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
5. Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDAs Office of New Drugs
6. Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
7. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
8. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
9. United Therapeutics Corporation Reports First Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
11. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the Baird 2015 ... . The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
(Date:9/2/2015)... , Sept. 2, 2015 Demers Ambulances is proud ... as their new dealer for the states of ... Tennessee . "This will enable ... Benoit Lafortune , Executive Vice-President for Demers Ambulances. "Emergency ... Mississippi and Alabama , giving ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
... , , SILVER SPRING, Md. , ... today approved Ampyra (dalfampridine) extended release tablets to improve walking ... treated with Ampyra had faster walking speeds than those treated ... approved for this use. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ...
... , ... People With All Types of Multiple Sclerosis , NEW ... Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known ... walking speed in people with any type of multiple sclerosis. ...
Cached Medicine Technology:FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:9/2/2015)... , ... September 03, 2015 , ... ... and frequently listed among the most influential leaders in healthcare, will offer the ... Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at the ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system ... complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or ... of any given guide RNA (sgRNA or crRNA) to create a break in the ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
... , , , ANNAPOLIS, ... PIP ), a biodefense company developing medical countermeasures against biological ... agreements for the issuance of 2-year, 10% unsecured senior convertible ... private placement of approximately $19.3 million. , , ...
... July 27 Health Robotics today announced,that it has ... to market,implement, and support its I.V. Workflow Engine and ... North America. One of,its software modules (OncoCube) has already ... University of Colorado Hospital [Denver], in,addition to all-digital ...
... , , , ... reveals that adults living in the country,s fifth largest city are ... and complex conditions. Many commonly used therapy classes including drugs to ... have experienced increases in adults 20 and older. , ...
... , Trinitas Comprehensive Cancer Center in Elizabeth, ... chemotherapy program in place , , LOS ... a variety of cancers--along with projections from the National Comprehensive Cancer Network ... by 2013--raise questions for both clinicians and patients with regard to the ...
... COLD SPRING HARBOR, N.Y., July 27 AccuVein LLC, ... illumination device, today announced that its quality system has received ... to customers around the globe AccuVein,s commitment to the quality ... and delivery procedures. , , ...
... , FRANKLIN, Mass., July 27 PLC ... innovative cardiac and vascular medical device-based technologies, today announced it ... capabilities provided by RenalGuard(R) from the Canadian Intellectual Property Office ... patent for RenalGuard in Canada. , , ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: